1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Bipolar Disorder (Manic Depression)-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Bipolar Disorder (Manic Depression)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Bipolar Disorder (Manic Depression). This report provides information on the therapeutic development based on the Bipolar Disorder (Manic Depression) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Bipolar Disorder (Manic Depression)
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Bipolar Disorder (Manic Depression)-Pipeline Insights, 2014
Table of Contents
- Bipolar Disorder (Manic Depression) Overview
- Bipolar Disorder (Manic Depression) Pipeline Therapeutics
- Bipolar Disorder (Manic Depression) Therapeutics under Development by Companies
- Bipolar Disorder (Manic Depression) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Bipolar Disorder (Manic Depression) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Bipolar Disorder (Manic Depression) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Bipolar Disorder (Manic Depression) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Bipolar Disorder (Manic Depression) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bipolar Disorder (Manic Depression) - Discontinued Products
- Bipolar Disorder (Manic Depression) - Dormant Products
- Companies Involved in Therapeutics Development for Bipolar Disorder (Manic Depression)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Bipolar Disorder (Manic Depression), 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Bipolar Disorder (Manic Depression) Assessment by Monotherapy Products
- Bipolar Disorder (Manic Depression) Assessment by Combination Products
- Bipolar Disorder (Manic Depression) Assessment by Route of Administration
- Bipolar Disorder (Manic Depression) Assessment by Stage and Route of Administration
- Bipolar Disorder (Manic Depression) Assessment by Molecule Type
- Bipolar Disorder (Manic Depression) Assessment by Stage and Molecule Type
- Bipolar Disorder (Manic Depression) Therapeutics - Discontinued Products
- Bipolar Disorder (Manic Depression) Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Bipolar Disorder (Manic Depression), 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Bipolar Disorder (Manic Depression) Assessment by Monotherapy Products
- Bipolar Disorder (Manic Depression) Assessment by Combination Products
- Bipolar Disorder (Manic Depression) Assessment by Route of Administration
- Bipolar Disorder (Manic Depression) Assessment by Stage and Route of Administration
- Bipolar Disorder (Manic Depression) Assessment by Molecule Type
- Bipolar Disorder (Manic Depression) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bipolar disorder (BPD)  - Market Insights, Epidemiology and Market Forecast-2023

Bipolar disorder (BPD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Bipolar disorder (BPD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Bipolar disorder (BPD) fo ...

Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

Bipolar disorder (BPD)  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Bipolar disorder (BPD)  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Bipolar disorder (BPD)  in seven major markets (US, France, Germany, Italy, ...

Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug ...


Download Unlimited Documents from Trusted Public Sources

Mental Health Statistics in the UK

  • November 2016
    297 pages
  • Mental Health  

  • United Kingdom  

View report >

Mental Health Statistics in the UK - Forecast

  • November 2016
    154 pages
  • Mental Health  

    Public Health  

  • United Kingdom  

    Europe  

    United States  

View report >

Mental Health Statistics in the US - Forecast

  • November 2016
    52 pages
  • Mental Health  

  • United States  

    North America  

View report >

Related Market Segments :

Bipolar Disorder
Depression

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.